caspocip caspofungin (as acetate) 50 mg powder for injection vial
cipla australia pty ltd - caspofungin acetate, quantity: 55.49 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sucrose; mannitol; glacial acetic acid; sodium hydroxide - caspocip is indicated for: ? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics ? treatment of: - invasive candidiasis, including candidaemia - oesophageal candidiasis - invasive aspergillosis in patients who are refractory to or intolerant of other therapies
caspocan powder for concentrate for solution for infusion 50 mgvial
teva pharmaceutical investments singapore pte. ltd. - caspofungin acetate 55.52mg equivalent to caspofungin - injection, powder, lyophilized, for solution - caspofungin acetate 55.52mg equivalent to caspofungin 50.00 mg/vial
caspocan powder for concentrate for solution for infusion 70 mgvial
teva pharmaceutical investments singapore pte. ltd. - caspofungin acetate 77.69mg equivalent to caspofungin - injection, powder, lyophilized, for solution - caspofungin acetate 77.69mg equivalent to caspofungin 70.00 mg/vial
caspofungin teva 50 mg powder for concentrate for solution for infusion
teva b.v. - caspofungin acetate - pdr/conc/soln for infus - 50 milligram(s) - other antimycotics for systemic use; caspofungin
caspofungin teva 70 mg powder for concentrate for solution for infusion
teva b.v. - caspofungin acetate - pdr/conc/soln for infus - 70 milligram(s) - other antimycotics for systemic use; caspofungin
caspofungin accord
accord healthcare s.l.u. - caspofungin acetate - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients.treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and/or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.
caspofungin sandoz caspofungin (as acetate) 50mg powder for injection
sandoz pty ltd - caspofungin acetate -
caspofungin sandoz caspofungin (as acetate) 70mg powder for injection
sandoz pty ltd - caspofungin acetate -
caspofungin powder for injection powder for solution
teva canada limited - caspofungin (caspofungin acetate) - powder for solution - 50mg - caspofungin (caspofungin acetate) 50mg - echinocandins
caspofungin powder for injection powder for solution
teva canada limited - caspofungin (caspofungin acetate) - powder for solution - 70mg - caspofungin (caspofungin acetate) 70mg - echinocandins